AKBA
Price
$2.24
Change
+$0.24 (+12.00%)
Updated
Mar 27, 6:59 PM EST
39 days until earnings call
FGEN
Price
$2.48
Change
-$0.10 (-3.88%)
Updated
Mar 28, 8:46 AM EST
39 days until earnings call
Ad is loading...

AKBA vs FGEN ᐉ Comparison: Which is Better to Invest?

Header iconAKBA vs FGEN Comparison
Open Charts AKBA vs FGENBanner chart's image
Akebia Therapeutics
Price$2.24
Change+$0.24 (+12.00%)
Volume$5.39M
CapitalizationN/A
FibroGen
Price$2.48
Change-$0.10 (-3.88%)
Volume$250
CapitalizationN/A
View a ticker or compare two or three
AKBA vs FGEN Comparison Chart

Loading...

AKBADaily Signal changed days agoGain/Loss if shorted
 
Show more...
FGENDaily Signal changed days agoGain/Loss if shorted
 
Show more...
VS
AKBA vs. FGEN commentary
Mar 28, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AKBA is a Hold and FGEN is a Hold.

COMPARISON
Comparison
Mar 28, 2024
Stock price -- (AKBA: $2.23 vs. FGEN: $2.58)
Brand notoriety: AKBA and FGEN are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: AKBA: 262% vs. FGEN: 57%
Market capitalization -- AKBA: $467.95M vs. FGEN: $254.34M
AKBA [@Biotechnology] is valued at $467.95M. FGEN’s [@Biotechnology] market capitalization is $254.34M. The market cap for tickers in the [@Biotechnology] industry ranges from $576.05B to $0. The average market capitalization across the [@Biotechnology] industry is $2.64B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

AKBA’s FA Score shows that 0 FA rating(s) are green whileFGEN’s FA Score has 0 green FA rating(s).

  • AKBA’s FA Score: 0 green, 5 red.
  • FGEN’s FA Score: 0 green, 5 red.
According to our system of comparison, FGEN is a better buy in the long-term than AKBA.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

AKBA’s TA Score shows that 6 TA indicator(s) are bullish while FGEN’s TA Score has 4 bullish TA indicator(s).

  • AKBA’s TA Score: 6 bullish, 4 bearish.
  • FGEN’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, AKBA is a better buy in the short-term than FGEN.

Price Growth

AKBA (@Biotechnology) experienced а +15.21% price change this week, while FGEN (@Biotechnology) price change was +9.11% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.99%. For the same industry, the average monthly price growth was +5.11%, and the average quarterly price growth was +89.03%.

Reported Earning Dates

AKBA is expected to report earnings on May 06, 2024.

FGEN is expected to report earnings on May 06, 2024.

Industries' Descriptions

@Biotechnology (+4.99% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
A.I.dvisor published
a Summary for AKBA with price predictions.
OPEN
A.I.dvisor published
a Summary for FGEN with price predictions.
OPEN
FUNDAMENTALS
Fundamentals
AKBA($468M) has a higher market cap than FGEN($254M). FGEN YTD gains are higher at: 190.534 vs. AKBA (80.242). AKBA has higher annual earnings (EBITDA): -4.05M vs. FGEN (-261.4M). FGEN has more cash in the bank: 236M vs. AKBA (42.9M). AKBA has less debt than FGEN: AKBA (48.1M) vs FGEN (153M). AKBA has higher revenues than FGEN: AKBA (195M) vs FGEN (148M).
AKBAFGENAKBA / FGEN
Capitalization468M254M184%
EBITDA-4.05M-261.4M2%
Gain YTD80.242190.53442%
P/E RatioN/AN/A-
Revenue195M148M132%
Total Cash42.9M236M18%
Total Debt48.1M153M31%
FUNDAMENTALS RATINGS
AKBA vs FGEN: Fundamental Ratings
AKBA
FGEN
OUTLOOK RATING
1..100
2126
VALUATION
overvalued / fair valued / undervalued
1..100
76
Overvalued
93
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
100100
PRICE GROWTH RATING
1..100
3435
P/E GROWTH RATING
1..100
10064
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

AKBA's Valuation (76) in the Biotechnology industry is in the same range as FGEN (93). This means that AKBA’s stock grew similarly to FGEN’s over the last 12 months.

AKBA's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as FGEN (100). This means that AKBA’s stock grew similarly to FGEN’s over the last 12 months.

AKBA's SMR Rating (100) in the Biotechnology industry is in the same range as FGEN (100). This means that AKBA’s stock grew similarly to FGEN’s over the last 12 months.

AKBA's Price Growth Rating (34) in the Biotechnology industry is in the same range as FGEN (35). This means that AKBA’s stock grew similarly to FGEN’s over the last 12 months.

FGEN's P/E Growth Rating (64) in the Biotechnology industry is somewhat better than the same rating for AKBA (100). This means that FGEN’s stock grew somewhat faster than AKBA’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
AKBAFGEN
RSI
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
90%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
86%
Bearish Trend 1 day ago
79%
Momentum
ODDS (%)
Bullish Trend 1 day ago
84%
Bullish Trend 1 day ago
85%
MACD
ODDS (%)
Bullish Trend 1 day ago
84%
Bullish Trend 1 day ago
90%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
84%
Bullish Trend 1 day ago
79%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
87%
Bullish Trend 1 day ago
78%
Advances
ODDS (%)
Bullish Trend 4 days ago
85%
Bullish Trend 4 days ago
80%
Declines
ODDS (%)
Bearish Trend 15 days ago
86%
Bearish Trend 22 days ago
81%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
88%
Bearish Trend 1 day ago
86%
Aroon
ODDS (%)
Bullish Trend 1 day ago
90%
Bullish Trend 1 day ago
72%
View a ticker or compare two or three
Ad is loading...
AKBADaily Signal changed days agoGain/Loss if shorted
 
Show more...
FGENDaily Signal changed days agoGain/Loss if shorted
 
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
IYEFX9.100.20
+2.25%
Delaware Climate Solutions R
JHLVX54.830.56
+1.03%
JHancock Fundamental Large Cap Core C
HFETX48.220.31
+0.65%
Janus Henderson European Focus T
GSCGX32.36N/A
N/A
Goldman Sachs Large Cap Core A
BABSX8.87N/A
N/A
BlackRock Global Equity Abs Rtn Instl